The below represents select transactions
EG 427
Announced: 02/20/2025 | Value: €27 million
MTS served as exclusive placement agent on EG 427’s Series B financing
Quartet Health
Announced: 01/31/2025 | Value: Undisclosed
MTS served as exclusive financial advisor to Quartet Health in its sale to NeuroFlow
innovaTel
Announced: 1/21/2025 | Value: Undisclosed
MTS served as exclusive financial advisor to Quartet Health on the sale of innovaTel, its telebehavioral health staffing business, to Iris Telehealth
Immedica Pharma AB
Announced: 12/30/2024 | Value: $151 million
Acquisition of Marinus Pharmaceuticals
Citizens Rx
Announced: 12/03/2024 | Value: Undisclosed
MTS served as exclusive financial advisor to Citizens Rx in its acquisition by LucyRx
BioLineRx
Announced: 11/21/2024 | Value: $97 million
MTS served as exclusive financial advisor to BioLineRx on its license agreement for motixafortide with Gamida Cell
Truepill
Announced: 10/01/2024 | Value: Undisclosed
MTS served as exclusive financial advisor to Truepill in its acquisition by LetsGetChecked
Blue Wolf Capital Partners
Announced: 09/25/2024 | Value: Undisclosed
MTS served as financial advisor to Blue Wolf Capital Partners on the creation of its new CDMO platform, combining the acquisitions of Recipharm and Synerlab
Osivax
Announced: 09/10/2024 | Value: Undisclosed
MTS served as exclusive financial advisor to Osivax on its license option agreement for its “Universal” influenza vaccine candidates in Japan with KM Biologics, a Meiji Group Company
Pharmacosmos A/S
Announced: 08/07/2024 | Value: $405 million
MTS served as exclusive financial advisor to Pharmacosmos A/S in its acquisition of G1 Therapeutics, Inc.
Sharecare
Announced: 06/21/2024 | Value: >$500 million
MTS served as financial advisor to Sharecare in its acquisition by Altaris, LLC
Asahi Kasei Corporation
Announced: 05/28/2024 | Value: $1.1 billion
MTS served as financial advisor to Asahi Kasei Corporation in its acquisition of Calliditas Therapeutics AB
AltruBio, Inc.
Announced: 05/21/2024 | Value: Up to $225 million
MTS acted as exclusive placement agent on AltruBio’s Series B financing of up to $225 million
Eden Health
Announced: 05/20/2024 | Value: Undisclosed
MTS served as exclusive financial advisor to Eden Health on its sale to Centivo
Sitka
Announced: 11/14/2023 | Value: Undisclosed
MTS served as exclusive financial advisor to Sitka on its merger with AristaMD
Redx Pharma
Announced: 10/18/2023 | Value: $17 million
MTS served as exclusive placement agent to Redx Pharma on its PIPE offering, which was priced at-the-money and with no warrant coverage
Applied Molecular Transport Inc.
Announced: 09/21/2023 | Value: Undisclosed
MTS served as exclusive financial advisor to Applied Molecular Transport Inc. in its merger with Cyclo Therapeutics Inc.
Zynerba Pharmaceuticals, Inc.
Announced: 08/14/2023 | Value: $60 million (plus up to $140 million in additional payments)
MTS served as exclusive financial advisor to Zynerba Pharmaceuticals, Inc. in its sale to Harmony Biosciences Holdings, Inc.
EQRx, Inc.
Announced: 08/01/2023 | Value: $1.1 billion
MTS served as financial advisor to EQRx, Inc. in its sale to Revolution Medicines
Quince Therapeutics
Announced: 07/24/2023 | Value: Up to $509 million
MTS served as exclusive financial advisor to Quince Therapeutics on its acquisition of EryDel
Limbix
Announced: 07/14/2023 | Value: Undisclosed
MTS served as exclusive financial advisor to Limbix in its sale to Big Health
Hisamitsu Pharmaceutical Co., Inc.
Announced: 07/13/2023 | Value: Undisclosed
MTS served as exclusive financial advisor to Hisamitsu Pharmaceutical in its acquisition of S-Cup and Lacalut brand from SSP Co., Ltd, a Sanofi Company
The Pill Club
Announced: 06/12/2023 | Value: Undisclosed
MTS served as exclusive financial advisor to The Pill Club in its sale of assets to Thirty Madison and Twentyeight Health
Chinook Therapeutics, Inc.
Announced: 06/12/2023 | Value: $3.2 billion
MTS served as financial advisor to Chinook Therapeutics on its sale to Novartis AG
Pear Therapeutics
Announced: 05/18/2023 | Value: Undisclosed
MTS served as exclusive financial advisor to Pear Therapeutics in its sale of assets to Click Therapeutics, Harvest Bio, Nox Health (Vestar), and Welt Corp.
CTI BioPharma
Announced: 05/10/2023 | Value: $1.7 billion
MTS served as financial advisor to CTI BioPharma on its sale to Swedish Orphan Biovitrum (SOBI)
Fujifilm
Announced: 05/10/2023 | Value: Undisclosed
MTS served as exclusive financial advisor to Fujifilm on its acquisition of remaining stake of Fujifilm Diosynth Biotechnologies group companies from Mitsubishi Corporation
Seagen Inc.
Announced: 03/13/2023 | Value: $43 billion
MTS served as financial advisor to Seagen on its sale to Pfizer
Concert Pharmaceuticals
Announced: 01/19/2023 | Value: Up to $831 million
MTS served as financial advisor to Concert Pharmaceuticals on its sale to Sun Pharmaceuticals
SavaSeniorCare
Announced: 12/20/2022 | Value: Undisclosed
MTS served as financial advisor to SavaSeniorCare on a restructuring plan whereby it relinquished operating control of all its skilled nursing facilities
Eisai
Announced: 12/19/2022 | Value: $160 million (plus milestone payments and royalties)
MTS served as exclusive financial advisor to Eisai on its divestiture of US rights for FYCOMPA® to Catalyst Pharmaceuticals
SCAN Group
Announced: 12/14/2022 | Value: Undisclosed
MTS serves as exclusive financial advisor to SCAN Group on its combination with CareOregon
BehaVR
Announced: 12/13/2022 | Value: Undisclosed
MTS served as exclusive financial advisor to BehaVR on its merger with OxfordVR
Minoryx Therapeutics
Announced: 11/10/2022 | Value: Up to €258 million
MTS serves as exclusive financial advisor to Minoryx Therapeutics on its exclusive European licensing agreement of Leriglitazone with Neuraxpharm Group
Horizon Blue Cross Blue Shield of New Jersey
Announced: 11/01/2022 | Value: Undisclosed
MTS served as exclusive financial advisor to Horizon Blue Cross Blue Shield of New Jersey in connection with its Mutualization
Aravive, Inc
Announced: 10/25/2022 | Value: $41 million
MTS served as exclusive placement agent to Aravive, Inc. on its PIPE offering
Applied Genetic Technologies Corporation (AGTC)
Announced: 10/23/2022 | Value: $73.5 million
MTS served as exclusive financial advisor to Applied Genetic Technologies Corporation (AGTC) on its sale to Syncona
Zymeworks, Inc.
Announced: 10/19/2022 | Value: $1.8 billion
MTS served as exclusive financial advisor to Zymeworks on its exclusive global licensing agreement of Zanidatamab with Jazz Pharmaceuticals
Horizon Blue Cross Blue Shield of New Jersey
Announced: 10/10/2022 | Value: Undisclosed
MTS served as exclusive financial advisor to Horizon Blue Cross Blue Shield of New Jersey in connection with the Expansion of Braven
Forefront Telecare
Announced: 9/1/2022 | Value: Undisclosed
MTS served as financial advisor to Forefront Telecare on its sale to SOC Telemed, a portfolio company of Patient Square Capital
DeliverLean
Announced: 8/29/2022 | Value: Undisclosed
MTS served as financial advisor to DeliverLean on its sale to NationsBenefits
JCR Pharmaceuticals
Announced: 7/27/2022 | Value: $45 million
MTS served as exclusive financial advisor to JCR Pharmaceuticals on its strategic minority equity investment in Mycenax Biotech
Theravance Biopharma
Announced: 7/13/2022 | Value: $1.5 billion
MTS served as financial advisor to Theravance Biopharma on its 85% economic interest sale of TRELEGY to Royalty Pharma
Epizyme, Inc.
Announced: 6/27/2022 | Value: $418 million
MTS served as financial advisor to Epizyme on its sale to Ipsen
Ring2Media
Announced: 6/16/2022 | Value: Undisclosed
MTS served as exclusive financial advisor to Ring2Media on its sale to Quote.com (a portfolio company of Osceola Capital)
Jvion
Announced: 5/31/2022 | Value: Undisclosed
MTS served as exclusive financial advisor to Jvion on its sale to Lightbeam Health Solutions (a portfolio company of Primus Capital)
SCAN Group
Announced: 5/26/2022 | Value: Undisclosed
MTS served as exclusive financial advisor to SCAN Group on its acquisition of The Residentialist Group
Entasis Therapeutics
Announced: 5/23/2022 | Value: $113 million
MTS served as exclusive financial advisor to Entasis Therapeutics on its sale to Innoviva
Sanderling Renal Services
Announced: 5/16/2022 | Value: Undisclosed
MTS served as exclusive financial advisor to Sanderling Renal Services on its growth equity investment by Pharos Capital
Botanix Pharmaceuticals
Announced: 5/3/2022 | Value: Up to $177 million
MTS served as exclusive financial advisor to Botanix Pharmaceuticals on its in-licensing of Sofpironium Bromide
Vytalize Health
Announced: 4/11/2022 | Value: $53 million
MTS served as the exclusive placement agent for Vytalize Health’s $53mm Series B financing
Lyra Therapeutics
Announced: 4/8/2022 | Value: $100 million
MTS served as exclusive placement agent to Lyra Therapeutics on its PIPE offering
Professional Health Care Network
Announced: 3/30/2022 | Value: Undisclosed
MTS served as exclusive financial advisor to Professional Health Care Network in its majority recapitalization by The Vistria Group
VectivBio
Announced: 3/30/2022 | Value: $25 million upfront, plus development cost sharing, milestones up to $170mm & double digit royalties
MTS served as exclusive financial advisor to VectivBio on its out-licensing of apraglutide in Japan to Asahi Kasei Pharma
Homology Medicines, Inc.
Announced: 1/28/2022 | Value: $130 million
MTS served as financial advisor to Homology Medicines in its partnership with Oxford Biomedica to form Oxford Biomedica Solutions LLC, with Homology as 20% owner
Fujifilm
Announced: 1/26/2022 | Value: $100 million
MTS served as exclusive financial advisor to Fujifilm in its acquisition of Atara Biotherapeutics’ T-cell Operations and Manufacturing (ATOM) facility
ADC Therapeutics SA
Announced: 1/18/2022 | Value: Upfront $30 million, plus milestones up to $205 million and double-digit royalties
MTS served as exclusive financial advisor to ADC Therapeutics on its out-licensing of ZYNLONTA in Japan to Mitsubishi Tanabe Pharma
Fuji Pharma
Announced: 12/28/2021 | Value: Undisclosed
MTS served as exclusive financial advisor to Fuji Pharma on its acquisition of SULPREP, MINCLEA, FOLIAMIN, and OSVAN in Japan from Nihon Pharma
Bellicum Pharmaceuticals
Announced: 12/6/2021 | Value: $35 million
MTS served as exclusive placement agent to Bellicum Pharmaceuticals on its PIPE offering
BehaVR
Announced: 10/18/2021 | Value: Up to $163 million
MTS served as exclusive financial advisor to BehaVR on its collaboration with Sumitomo Dainippon Pharma
One Medical Passport
Announced: 10/5/2021 | Value: Undisclosed
MTS served as exclusive financial advisor to One Medical Passport on its sale to Mnet Health
JCR Pharmaceuticals Co., Ltd.
Announced: 9/30/2021 | Value: Undisclosed
MTS served as exclusive financial advisor to JCR Pharmaceuticals on its collaboration and license agreement to commercialize JR-141 with Takeda Pharmaceutical
Arbor Pharmaceuticals, Inc
Announced: 8/24/2021 | Value: Undisclosed
MTS served as exclusive financial advisor to Arbor Pharmaceuticals on its sale to Azurity Pharmaceuticals
ImmunoTek
Announced: 7/30/2021 | Value: Undisclosed
MTS served as exclusive financial advisor to ImmunoTek on its development and supply agreement with Grifols
MedRhythms
Announced: 7/28/2021 | Value: $25 million
MTS served as exclusive placement agent to MedRhythms on its $25 million Series B financing
Otsuka Pharmaceutical
Announced: 7/23/2021 | Value: $20 million
MTS served as the exclusive financial advisor to Otsuka America Pharmaceutical on the divestiture of its North American BreathTek business to Meridian Bioscience
Seres Therapeutics, Inc.
Announced: 7/1/2021 | Value: $525 million
MTS served as the exclusive financial advisor to Seres Therapeutics on its co-commercialization license agreement with Nestlé Health Science for SER-109
Catalyst Pharmaceuticals, Inc.
Announced: 6/28/2021 | Value: Undisclosed
MTS served as the exclusive financial advisor to Catalyst Pharmaceuticals on its outlicensing of Firdapse in Japan to DyDo Pharma
onehome
Announced: 6/14/2021 | Value: Undisclosed
MTS served as lead financial advisor to onehome on its sale to Humana
Kinderhook Industries, Inc.
Announced: 6/14/2021 | Value: Undisclosed
MTS served as exclusive financial advisor to Kinderhook Industries’ portfolio company on acquisition of Medical Card System
Strongbridge Biopharma
Announced: 5/24/2021 | Value: $267 million
MTS served as exclusive financial advisor to Strongbridge Biopharma on its sale to Xeris Pharmaceuticals
Synzi
Announced: 5/7/2021 | Value: $42.5 million
MTS served as exclusive financial advisor to Synzi on its sale to AMN Healthcare
Genesis Healthcare
Announced: 03/03/2021 | Value: Undisclosed
MTS served as exclusive financial advisor to Genesis Healthcare in connection with its restructuring
Applied Genetic Technologies Corporation (AGTC)
Announced: 1/28/2021 | Value: $75 million
Joint bookrunner and financial advisor on the confidentially marketed public offering (CMPO) for Applied Genetic Technologies Corporation (NASDAQ: AGTC)
Acorda Therapeutics
Announced: 1/13/2021 | Value: $80 million
MTS served as exclusive financial advisor to Acorda on its sale of a spray drying manufacturing facility
Magellan Health, Inc.
Announced: 12/22/2020 | Value: Undisclosed
MTS served as exclusive financial advisor to Magellan on its acquisition of a majority interest in Bayless Integrated Healthcare
Neos Therapeutics, Inc.
Announced: 12/10/2020 | Value: Undisclosed
MTS served as exclusive financial advisor to Neos Therapeutics on its stock-for-stock merger with Aytu Bioscience
Sunesis Pharmaceuticals, Inc.
Announced: 11/30/2020 | Value: Undisclosed
Financial advisor to Sunesis Pharmaceuticals, Inc. on its all-stock merger with Viracta Therapeutics, Inc.
Cystic Fibrosis Foundation
Announced: 11/2/2020 | Value: $575 million upfront plus a $75 million potential milestone payment
MTS served as exclusive financial advisor to the Cystic Fibrosis Foundation in the structured sale of its residual royalty interests in Vertex’s Cystic Fibrosis Assets
Magellan Health, Inc.
Announced: 10/29/2020 | Value: Undisclosed
MTS served as exclusive financial advisor to Magellan on its strategic minority equity investment in Kaden Health
doctor.com
Announced: 10/13/2020 | Value: Undisclosed
MTS served as exclusive financial advisor to doctor.com on its sale to Press Ganey Associates
University of Maryland Medical System
Announced: 10/12/2020 | Value: Undisclosed
Exclusive financial advisor to the University of Maryland Medical System in connection with the sale of its Medicare and Medicaid plans to CareFirst Blue Cross Blue Shield
Galecto Inc.
Announced: 9/25/2020 | Value: $64 million
Placement agent for Galecto Inc. on its $64mm Crossover financing
Strongbridge Biopharma
Announced: 9/16/2020 | Value: $25 million
MTS served as financial advisor to Strongbridge Biopharma on its public offering
MiNA Therapeutics
Announced: 9/10/2020 | Value: £23 million
Exclusive placement agent for MiNA Therapeutics on its £23 million ($30mm) Series A financing
Verastem Oncology
Announced: 8/10/2020 | Value: Up to $311 million plus double-digit royalty on US + EU sales and 50% of net royalties on previously out licensed regions
MTS served as financial advisor to Verastem Oncology in Sale of COPIKTRA to Secura Bio
Lexicon Pharmaceuticals
Announced: 7/30/2020 | Value: Up to $224 million
MTS served as financial advisor to Lexicon Pharmaceuticals in Sale of XERMELO to TerSera Therapeutics
Healthcare Merger Corp
Announced: 7/29/2020 | Value: $720 million
MTS served as financial advisor to Healthcare Merger Corp on its merger with SOC Telemed
Chinook Therapeutics
Announced: 6/2/2020 | Value: Undisclosed
Exclusive financial advisor to Chinook Therapeutics on its all-stock reverse merger with Aduro Biotech
Larimar Therapeutics
Announced: 5/29/2020 | Value: $80 million
MTS Served as exclusive placement agent to Larimar Therapeutics (NASDAQ:LRMR) on its $80mm PIPE financing
Geron Corporation
Announced: 5/21/2020 | Value: $150 million
Joint bookrunner on the confidentially marketed public offering for Geron Corporation (NASDAQ: GERN)
scPharmaceuticals
Announced: 5/20/2020 | Value: $50 million
MTS served as financial advisor in public offering of common stock
Quorum Health Corporation
Announced: 4/7/2020 | Value: $1.3 billion
MTS served as exclusive financial advisor to Quorum in connection with the prepackaged Chapter 11 recapitalization
JCR Pharmaceuticals Co., Ltd
Announced: 3/26/2020 | Value: Undisclosed
MTS served as exclusive financial advisor to JCR Pharmaceuticals (TSE:4552) on its acquisition of ArmaGen
Zyla Life Sciences
Announced: 3/16/2020 | Value: Undisclosed
MTS served as exclusive financial advisor to Zyla Life Sciences on its stock-for-stock merger with Assertio Therapeutics
Pager, Inc.
Announced: 3/9/2020 | Value: $33 million
Exclusive financial advisor to Pager on its $33mm private placement
Lincare
Announced: 3/4/2020 | Value: Undisclosed
MTS served as exclusive financial advisor to Lincare on its sale of Home Infusion assets to KabaFusion
R1 RCM
Announced: 1/13/2020 | Value: $190 million
Served as financial advisor to R1 RCM (NASDAQ: RCM) on its acquisition of SCI Solutions
Universal Care, Inc. (d/b/a/ Brand New Day)
Announced: 1/8/2020 | Value: $280 million
Exclusive financial advisor to Universal Care, Inc. (d/b/a/ Brand New Day) on its sale to Bright Health
Healthgrades
Announced: 1/7/2020 | Value: Undisclosed
MTS served as exclusive financial advisor to Healthgrades on its acquisition of Evariant
Gilead Sciences, Inc.
Announced: 12/24/2019 | Value: Undisclosed
Exclusive financial advisor to Gilead Sciences on its co-promotion of FILGOTINIB with Eisai in Japan
Zafgen, Inc.
Announced: 12/18/2019 | Value: Undisclosed
Exclusive financial advisor to Zafgen, Inc. on its all-stock merger with Chondrial Therapeutics, Inc.
Veloxis Pharmaceuticals A/S
Announced: 11/25/2019 | Value: $1.318 billion
Exclusive financial advisor to Veloxis on its sale to Asahi Kasei Group
Blue Cross and Blue Shield of Arizona, Inc.
Announced: 11/7/2019 | Value: Undisclosed
Exclusive financial advisor to Blue Cross and Blue Shield of Arizona, Inc. on its pending acquisition of Steward Health Choice Arizona from Steward Health Care System
Roivant Sciences
Announced: 10/31/2019 | Value: $3.0 billion
Exclusive financial advisor to Roivant in its sale of select assets, access to Health technology, and 10% equity to Dainippon Sumitomo Pharma
Genesis HealthCare
Announced: 10/16/2019 | Value: $89 million for the sale of 8 facilities and undisclosed value of JV in 18 facilities with undisclosed investor
MTS served as financial advisor to Genesis Healthcare on its sale of 8 facilities and formation of a joint venture in 18 facilities with an undisclosed investor
H. Lundbeck A/S
Announced: 9/16/2019 | Value: $2.0 billion
MTS served as financial advisor to Lundbeck on its acquisition of Alder BioPharmaceuticals
Cavion, Inc.
Announced: 8/12/2019 | Value: Up to $312.5 million
Exclusive financial advisor to Cavion in connection with its sale to Jazz Pharmaceuticals
Neoleukin Therapeutics, Inc.
Announced: 8/6/2019 | Value: Undisclosed
Exclusive financial advisor to Neoleukin Therapeutics on its reverse merger with Aquinox Pharmaceuticals
Vical Incorporated
Announced: 6/3/2019 | Value: Undisclosed
Exclusive Financial Advisor to Vical Incorporated on its all-stock merger with Brickell Biotech, Inc.
Amryt Pharma plc
Announced: 5/21/2019 | Value: $518 million in combined enterprise value, plus up to an additional $85mm in CVRs to Amryt shareholders
Exclusive financial advisor to Amryt Pharma plc on its all-stock merger with Aegerion Pharmaceuticals, Inc.
LifeArc
Announced: 5/20/2019 | Value: $1.297 billion
MTS served as exclusive financial advisor to LifeArc on the structured sale of a portion of its worldwide royalty interests in Keytruda
Realm Therapeutics
Announced: 5/16/2019 | Value:
Financial advisor to Realm Therapeutics on its reverse merger with ESSA Pharma
University of Newcastle upon Tyne
Announced: 4/1/2019 | Value: $31 million
Exclusive financial advisor to Newcastle University in the structured sale of a portion of its royalty interests in RUBRACA
Promise Healthcare
Announced: 2/13/2019 | Value: $84 million
Exclusive financial advisor to Promise Healthcare Group in its Section 363 sale of Silver Lake Medical Center to L.A. Downtown Medical Center
Arsenal Capital Partners
Announced: 1/17/2019 | Value: Undisclosed
MTS served as exclusive financial advisor to Arsenal Capital Partners on its acquisition of Accumen Inc.
Activate Healthcare
Announced: 1/16/2019 | Value: Undisclosed
MTS served as exclusive financial advisor to Activate Healthcare on its acquisition by Paladina Health.
SMV Property Holdings
Announced: 1/11/2019 | Value: $835 million
MTS Health Partners acted as exclusive financial advisor to SMV Property Holdings in connection with a $835mm refinancing
Immunogen, Inc.
Announced: 1/8/2019 | Value: $65 million
Exclusive financial advisor to ImmunoGen on its sale of residual Kadcyla royalties
Shionogi & Co., Ltd.
Announced: 12/19/2018 | Value: Upfront of $5 million and equity investment of $35 million, plus milestones up to $120mm and tiered royalty on sales if successfully commercialized
Exclusive financial advisor to Shionogi on its strategic collaboration with Tetra Discovery Partners to license Tetra’s BPN14770 in Japan, Taiwan and Korea.
Strongbridge Biopharma
Announced: 10/31/2018 | Value: ~$182 million cash and PIPE investment plus additional undisclosed amount for inventory and sales force for three years
Exclusive financial advisor to Strongbridge Biopharma on its sale of US and Canadian rights for Macrilen to Novo Nordisk
Adynxx
Announced: 10/12/2018 | Value: Undisclosed
Exclusive financial advisor to Adynxx on its all-stock merger agreement with Alliqua BioMedical
Otsuka Pharmaceutical
Announced: 10/11/2018 | Value: $80 million
Exclusive Financial Advisor to Otsuka on its expanded collaboration agreement with Proteus to Advance Digital Medicines For Mental Health
Poxel
Announced: 8/30/2018 | Value: Upfront ~$18 million, plus additional undisclosed development and commercial milestones
Exclusive financial advisor to Poxel on its acquisition of DRX-065 and other programs from DeuteRx
Ligand Pharmaceuticals
Announced: 8/9/2018 | Value: £32.8 million
Financial advisor to Ligand Pharmaceuticals in its acquisition of Vernalis
Psyadon Pharmaceuticals
Announced: 8/8/2018 | Value: Undisclosed
Exclusive financial advisor to Psyadon Pharmaceuticals in connection with its sale to Paragon Biosciences
ReViral
Announced: 8/1/2018 | Value: $55 million
Exclusive placement agent for ReViral Ltd on its $55mm Series B financing
Protalix BioTherapeutics
Announced: 7/24/2018 | Value: Up to $805 million
Exclusive financial advisor to Protalix on its sale of the U.S. commercialization and development rights for PRX-102 to Chiesi Farmaceutici
Apollo Global Management / RCCH HealthCare Partners
Announced: 7/23/2018 | Value: $5.6 billion
MTS served as financial advisor to Apollo/RCCH on its $5.6 Billion Cash Merger with LifePoint Health (NASDAQ: LPNT)
Jazz Pharmaceuticals
Announced: 6/29/2018 | Value: $80 million
Exclusive Financial Advisor to Jazz Pharmaceuticals in its sale of Prialt to TerSera Therapeutics.
Dana-Farber Cancer Institute
Announced: 6/29/2018 | Value: Undisclosed
MTS served as exclusive financial advisor to Dana-Farber on the sale of royalty interests
Keryx Biopharmaceuticals
Announced: 6/28/2018 | Value: $1.3 billion
Financial advisor to Keryx Biopharmaceuticals in its all-stock merger with Akebia Therapeutics
University of Massachusetts Medical School
Announced: 6/22/2018 | Value: Undisclosed
Exclusive financial advisor to the University of Massachusetts Medical School in the structured sale of a portion of its US royalty interests in SPINRAZA
Boston Children’s Hospital
Announced: 6/19/2018 | Value: $51.5 million
Exclusive financial advisor to Boston Children’s Hospital in the structured sale of royalty interests in VONVENDI
Shionogi & Co., Ltd.
Announced: 6/13/2018 | Value: Upfront $90 million, plus additional development and commercial milestones of up to $485 million
Exclusive financial advisor to Shionogi on its strategic collaboration with Sage Therapeutics to develop and commercialize SAGE-217 in Japan, Taiwan and South Korea
Cold Spring Harbor Laboratory
Announced: 6/12/2018 | Value: Undisclosed
Exclusive financial advisor to CSHL in the structured sale of a portion of its worldwide royalty interests in SPINRAZA
Cyteir Therapeutics
Announced: 4/30/2018 | Value: $35 million
Sole placement agent
Arbutus Biopharma
Announced: 4/11/2018 | Value: Undisclosed
MTS advised the Special Committee to the Board of Directors of Arbutus on the launch of Genevant Sciences, a jointly-owned company with Roivant Sciences
pSivida
Announced: 3/28/2018 | Value: Up to $125 million
Exclusive financial advisor to pSivida in connection with its acquisition of Icon Bioscience to form EyePoint Pharmaceuticals
Ameritox
Announced: 3/5/2018 | Value: Undisclosed
Exclusive financial advisor to Ameritox in connection with its sale to Aegis Sciences Corporation, a portfolio company of Abry Partners
Addex Therapeutics
Announced: 3/5/2018 | Value: $42.6 million
Sole US placement agent for Addex Therapeutics (SWX: ADXN) in connection with a $42.6 million PIPE financing
Churchill Pharmaceuticals
Announced: 1/25/2018 | Value: Undisclosed Partner
Exclusive financial advisor to Churchill Pharmaceuticals on its outlicensing of YONSA to an Undisclosed Partner
Strongbridge Biopharma
Announced: 1/17/2018 | Value: Up to $203 million
Acquisition of US and Canadian rights to MACRILEN from Aeterna Zentaris
Novozymes
Announced: 12/28/2017 | Value: Undisclosed
Exclusive financial advisor to Novozymes on the divestiture of Albumedix
ImmusanT
Announced: 11/14/2017 | Value: $40 million
Sole placement agent in Series C private financing
Ocera Therapeutics
Announced: 11/2/2017 | Value: Up to $117 million
Clinical-stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous (IV) and oral formulations
Envisia Therapeutics
Announced: 10/5/2017 | Value: $25 million plus additional undisclosed product approval milestones
Exclusive financial advisor to Envisia Therapeutics on its asset sale to Aerie Pharmaceuticals
Arbutus Biopharma
Announced: 10/2/2017 | Value: $116.4 million
Financial Advisor to Special Committee of the Board of Directors on Private Placement
Dimension Therapeutics
Announced: 10/2/2017 | Value: $171 million
Exclusive financial advisor to Dimension Therapeutics in connection with its sale to Ultragenyx Pharmaceutical
Realm Therapeutics
Announced: 9/21/2017 | Value: $26 million
Realm Therapeutics (AIM:RLM) announced an upsized $26 million private placement
Walter and Eliza Hall Institute
Announced: 7/27/2017 | Value: $325 million
Exclusive financial advisor to WEHI in the structured sale of a portion of its worldwide royalty interests in venetoclax
Physicians Dialysis and GMF Capital
Announced: 5/1/2017 | Value: Undisclosed
Exclusive financial and debt advisor to Physicians Dialysis and GMF Capital in connection with acquisition of assets from DaVita
Zymeworks
Announced: 4/27/2017 | Value: $59 million
Financial advisor to Zymeworks in connection with its IPO
Verona Pharma plc
Announced: 4/26/2017 | Value: $80 million
Financial advisor to Verona Pharma in connection with its U.S. IPO
Caladrius Biosciences
Announced: 3/16/2017 | Value: $75 million upfront, plus $5 million additional potential sales milestone payment
Exclusive financial advisor to Caladrius Biosciences on the sale of its remaining 80.1% equity stake in its PCT, LLC subsidiary
Otsuka Pharmaceutical
Announced: 3/2/2017 | Value: $100 million upfront, plus up to $150mm in development & regulatory milestones, plus additional potential sales milestone payments
Exclusive financial advisor to Otsuka Pharmaceutical Co., Ltd. on its acquisition of Neurovance, Inc.
Arizona Center for Cancer Care
Announced: 1/30/2017 | Value: Undisclosed
Exclusive financial advisor to AZCCC in connection with its Joint Venture with HonorHealth
CoLucid Pharmaceuticals
Announced: 1/18/2017 | Value: $960 million
Exclusive sell-side advisor to CoLucid Pharmaceuticals on its sale to Eli Lilly and Company
Ipsen
Announced: 1/8/2017 | Value: $575 million plus up to $450 million in contingent payments
Exclusive financial advisor to Ipsen on its acquisition of Onivyde from Merrimack Pharmaceuticals
OncoGenex Pharmaceuticals
Announced: 1/5/2017 | Value: Undisclosed
Exclusive financial advisor to OncoGenex Pharmaceuticals on its all-stock merger agreement with Achieve Life Science
Shire plc (NASDAQ:SHPG)
Announced: 1/4/2017 | Value: Undisclosed
Exclusive financial advisor to Shire on the spin-out of its MRT platform to RaNA Therapeutics
Universal American
Announced: 11/17/2016 | Value: $800 million
MTS advised Universal American on its sale to WellCare Health Plans
Ocular Technologies (an Auven Therapeutics portfolio company)
Announced: 10/26/2016 | Value: $40 million plus contingent payments
Exclusive financial advisor to Auven Therapeutics in the sale of Seciera, a Phase 3 clinical asset for the treatment of dry eye disease
Horizon Pharma Plc
Announced: 9/12/2016 | Value: $800 million
Lead financial advisor to Horizon Pharma Plc on its acquisition of Raptor Pharmaceutical
PathGroup
Announced: 8/1/2016 | Value: Undisclosed
Exclusive financial advisor to PathGroup in connection with its sale to Pritzker Group Private Capital
Dana-Farber Cancer Institute
Announced: 7/29/2016 | Value: $168 million
Long-term exclusive financial advisor to DFCI in the structured sale of a portion of its royalty interests in certain PD-L1 products and product candidates
Medical Research Council Technology
Announced: 7/8/2016 | Value: $150 million
Exclusive financial advisor to MRCT in the structured sale of a portion of its worldwide royalty interests in KEYTRUDA
Bloom Health
Announced: 07/06/2016 | Value: Undisclosed
Sole advisor to Bloom Health on its sale to Empyrean Benefit Solutions
Verona Pharma
Announced: 06/17/2016 | Value: $63.3 million
Sole US placement agent for Verona Pharma in connection with raising $63.3 million in a PIPE financing
Celator Pharmaceuticals
Announced: 05/31/2016 | Value: $1.5 billion
Exclusive financial advisor to Celator in connection with its sale to Jazz Pharmaceuticals
Synta Pharmaceuticals
Announced: 04/14/2016 | Value: Undisclosed
Financial Advisor to Synta Pharmaceuticals on its all-stock merger agreement with Madrigal Pharmaceuticals
Madrigal Pharmaceuticals
Announced: 04/14/2016 | Value: Undisclosed
Strategic Advisor to Madrigal Pharmaceuticals on its all-stock merger agreement with Synta Pharmaceuticals
Starmount
Announced: 04/04/2016 | Value: $127 million
Exclusive financial advisor to Starmount in connection with its sale to Unum Group (NYSE: UNM)
Celator Pharmaceuticals
Announced: 03/23/2016 | Value: $44 million
Financial advisor to Celator Pharmaceuticals (NASDAQ:CPXX) on its $43.7 Million Public Offering
Caladrius Biosciences
Announced: 03/14/2016 | Value: $25 million
Exclusive financial advisor to Caladrius Biosciences on its Strategic Global Collaboration and Asia License Agreement with Hitachi Chemical (19.9% Equity Stake for $19.4 Million and $5.6 Million Upfront)
Signature Hospice and Home Health
Announced: 03/09/2016 | Value: $84 million
Exclusive financial advisor to Genesis Healthcare (NYSE: GEN) on the sale of its Signature Hospice and Home Health operations to Hospice Compassus
Laurel Health Care Company
Announced: 02/02/2016 | Value: Undisclosed
Sale of real estate assets to Omega Healthcare Investors as well as the sale of operations to Ciena Healthcare
Tarveda Therapeutics (formerly Blend Therapeutics)
Announced: 01/27/2016 | Value: $38 million
Sole placement agent for Tarveda Therapeutics on its $38 Million Private Placement
Acorda Therapeutics
Announced: 01/19/2016 | Value: $363 million
Financial advisor to Acorda Therapeutics on the acquisition of Biotie Therapies
Aprecia Pharmaceuticals
Announced: 01/14/2016 | Value: $50 million
Sole placement agent for Aprecia Pharmaceuticals on its $50 Million Private Placement
Zymeworks
Announced: 01/08/2016 | Value: $62 million
Lead placement agent for Zymeworks in connection with raising $61.5 million of Series A financing
Diffusion Pharmaceuticals LLC
Announced: 12/15/2015 | Value: Undisclosed
Exclusive financial advisor to Diffusion Pharmaceuticals on its merger with RestorGenex Corporation
Velicept Therapeutics
Announced: 11/24/2015 | Value: $20 million
Sole placement agent for Velicept Therapeutics on its $20 million Private Placement
Examination Management Services Inc.
Announced: 11/03/2015 | Value: Undisclosed
Exclusive financial advisor to EMSI in connection with its sale to Beecken Petty O’Keefe
StrataDx
Announced: 10/01/2015 | Value: Undisclosed
Exclusive financial advisor to StrataDx in connection with its sale to Dermatopathology Experts
Health Diagnostic Laboratory
Announced: 09/11/2015 | Value: $37.1 million
Financial advisor to HDL in its Section 363 sale to True Health Diagnostics
Tripex Pharmaceuticals
Announced: 08/20/2015 | Value: $418.4 million
Exclusive advisor for Tripex in connection with its sale of Quinsair to Raptor Pharmaceuticals
Celsus Therapeutics
Announced: 08/18/2015 | Value: $75 million
Placement agent for Celsus in connection with raising $75 million in a PIPE financing
TeamHealth
Announced: 08/04/2015 | Value: $1.6 billion
Financial advisor to TeamHealth on its acquisition of IPC Healthcare
Celsus Therapeutics
Announced: 07/13/2015 | Value: Undisclosed
Financial advisor to Celsus Therapeutics on its merger with Volution Immuno Pharmaceuticals
ARCA biopharma
Announced: 06/11/2015 | Value: $37 million
Sole placement agent for ARCA biopharma in connection with raising $37 million in a PIPE financing
University of Maryland Medical System
Announced: 05/14/2015 | Value: Not Disclosed
Exclusive advisor for the University of Maryland Medical System in connection with its acquisition of Riverside Health
Baxter International Inc.
Announced: 05/12/2015 | Value: $900 million
Financial advisor to Baxter International Inc. on its acquisition of Oncaspar Portfolio from Sigma-Tau Finanziaria S.p.A
ImmunoGen, Inc.
Announced: 03/30/2015 | Value: $200 million
Exclusive financial advisor to ImmunoGen, Inc. in the structured sale of a portion of its worldwide royalty interests in Kadcyla
Champions Oncology
Announced: 03/12/2015 | Value: $14 million
Sole placement agent for Champions Oncology in connection with raising $14 million in a PIPE financing
TRACON Pharmaceuticals, Inc.
Announced: 01/29/2015 | Value: $41 million
Financial advisor to TRACON Pharmaceuticals, Inc. in connection with its Initial Public Offering
Regado Biosciences
Announced: 01/14/2015 | Value: Not Disclosed
Financial advisor to Regado Biosciences on its merger with Tobira Therapeutics
Otsuka Pharmaceutical
Announced: 12/02/2014 | Value: $3.54 billion
Financial advisor to Otsuka Pharmaceutical Co., Ltd. on its acquisition of Avanir Pharmaceuticals, Inc.
Community Health Systems
Announced: 11/07/2014 | Value: Not Disclosed
Exclusive financial advisor to Community Health Systems on its divestiture of Riverview Regional Medical Center to Prime Healthcare Services
GE Capital, Healthcare Financial Services
Announced: 11/05/2014 | Value: $305 million
Exclusive financial advisor to GE Capital, Healthcare Financial Services in its sale of a Long Term Care Real Estate Portfolio to Aviv REIT
Paul Capital
Announced: 10/17/2014 | Value: Not Disclosed
Exclusive financial advisor to Paul Capital on the secondary sale of royalty streams generated by seven pharmaceuticals
Community Health Systems
Announced: 10/13/2014 | Value: Not Disclosed
Exclusive financial advisor to Community Health Systems on its divestiture of Carolina Pines Regional Medical Center to Capella Healthcare
WellSpring Pharmaceutical
Announced: 10/03/2014 | Value: Not Disclosed
Exclusive financial advisor to WellSpring Pharmaceutical Corporation on the sale of its Prescription Pharmaceutical Business
Acorda Therapeutics
Announced: 09/24/2014 | Value: $525 million
Financial advisor to Acorda Therapeutics on the acquisition of Civitas Therapeutics
TRACON Pharmaceuticals
Announced: 09/22/2014 | Value: $27 million
Lead placement agent for Tracon in connection with raising $27.0 million of Series B financing
Aerie Pharmaceuticals, Inc.
Announced: 09/09/2014 | Value: $125 million
Exclusive financial advisor to Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) to enter into a $125m secured convertible debt facility agreement with Deerfield Capital Management for continued development of product pipeline (Rhopressa™ and Roclatan™), general corporate purposes, and strategic growth opportunities
Skilled Healthcare Group
Announced: 08/18/2014 | Value: NA
Exclusive financial advisor to Skilled Healthcare Group Inc. (NYSE:SKH) on its merger with Genesis HealthCare
AesRx
Announced: 07/09/2014 | Value: Not Disclosed
Exclusive financial advisor to AesRx, LLC on its sale to Baxter International Inc.
Nicox
Announced: 07/02/2014 | Value: Up to $120 million
Exclusive financial advisor to Nicox, SA on its acquisition of Aciex Therapeutics, Inc.
Vistria
Announced: 06/24/2014 | Value: Not Disclosed
Financial advisor to Vistria on its acquisition of Angel MedFlight
Cymetrix
Announced: 05/14/2014 | Value: Up to $100 million
Financial advisor to Cymetrix on its sale to Navigant
Alder Biopharmaceuticals Inc
Announced: 05/08/2014 | Value: $80 million
Financial advisor to Alder Biopharmaceuticals Inc in connection with its Initial Public Offering
Corrona
Announced: 04/17/2014 | Value: Not Disclosed
MTS acted as financial advisor on the growth recapitalization of Corrona
Kaléo
Announced: 04/07/2014 | Value: $150 million
Exclusive financial advisor to kaléo to enter into a $150 million debt facility with PDL BioPharma (NASDAQ: PDLI) to enable kaléo to support commercialization of EVZIO™ (naloxone hydrochloride injection) and development of key pipeline products
Promise Healthcare
Announced: 04/02/2014 | Value: Not Disclosed
Financial advisor to Promise Healthcare, Inc. on its acquisition of six healthcare facilities including four long-term acute care hospitals and two skilled nursing facilities
Oxygen Biotherapeutics
Announced: 03/18/2014 | Value: $59.8 million
MTS served as underwriter for the transaction and led efforts with institutional investors participating in the offering
Promise Healthcare
Announced: 03/17/2014 | Value: Not Disclosed
Financial advisor to Promise Healthcare, Inc. on its restructuring
NuPathe Inc.
Announced: 01/21/2014 | Value: $268 million
Financial advisor to NuPathe Inc. on its sale to Teva Pharmaceutical Industries.
Iroko Pharmaceuticals
Announced: 11/21/2013 | Value: $75 million
Exclusive financial advisor to Iroko to enter into a $75m debt facility agreement to support general business operations and the launch of Zorvolex (diclofenac)
Almost Family, Inc.
Announced: 11/5/2013 | Value: $75.5 million
Financial advisor to Almost Family, Inc. on its acquisition of SunCrest Healthcare
Miraca Life Sciences
Announced: 10/23/2013 | Value: Not Disclosed
Financial advisor to Miraca Life Sciences on its acquisition of PLUS Diagnostics
La Jolla Pharmaceutical
Announced: 09/25/2013 | Value: $10 million
Sole placement agent for La Jolla Pharmaceutical Company in connection with raising $10.0 million through common and preferred shares
Celsus Therapeutics
Announced: 09/19/2013 | Value: $12.5 million
Placement agent for Celsus Therapeutics in connection with raising $12.5 million through common shares
QuantiaMD
Announced: 9/3/2013 | Value: $10 million
Sole placement agent for Quantia Communications, Inc. on its $10 million Private Placement
Acorda Therapeutics
Announced: 7/9/2013 | Value: Not Disclosed
Financial advisor to Acorda Therapeutics on the acquisition of Qutenza™ and NP-1998 from NeurogesX
University of Pennsylvania
Announced: 6/25/2013 | Value: $55 million
Exclusive financial advisor to University of Pennsylvania in the structured sale of a portion of its worldwide royalty interests in Juxtapid
Laboratory Partners
Announced: 6/3/2013 | Value: Not Disclosed
Financial advisor to Laboratory Partners on the sale of its physician outreach business
AmeriHealth Caritas
Announced: 5/1/2013 | Value: Not Disclosed
Financial advisor to AmeriHealth Caritas on its acquisition of DC Chartered Health Plan assets
RXi Pharmaceuticals Corporation
Announced: 3/1/2013 | Value: $16.4 million
Sole placement agent for RXI Pharmaceuticals Corp. in connection with raising $16.4 million through the sale of common shares
Progenics Pharmaceuticals
Announced: 1/22/2013 | Value: Up to $105 million
Financial advisor to Progenics Pharmaceuticals, Inc on its acquisition of Molecular Insight Pharmaceuticals
TractManager Inc.
Announced: 1/7/2013 | Value: Not Disclosed
Exclusive financial advisor to TractManager, Inc. in connection with the majority recapitization investment by Arsenal Capital Partners
Florida Clinical Laboratory
Announced: 12/31/2012 | Value: Not Disclosed
Exclusive financial advisor to Florida Clinical Laboratory on its sale to Bio-Reference Laboratories, Inc.
BioScrip
Announced: 12/13/2012 | Value: $70 million
Financial advisor to BioScrip Inc. on its acquisition of HomeChoice Partners, Inc. from DaVita HealthCare Partners
GE Capital, Healthcare Financial Services
Announced: 12/1/2012 | Value: Not Disclosed
Exclusive financial advisor to GE Healthcare Financial Services in its sale of a Long Term Care Real Estate Portfolio to Formation Capital
MethylGene
Announced: 11/21/2012 | Value: $26 million
Acted as a placement agent for MethylGene in connection with raising $26MM in a PIPE financing
NuPathe
Announced: 10/23/2012 | Value: $28 million
Co-placement agent for NuPathe, Inc. in connection with raising $28 million in a PIPE financing
Fibrocell Science
Announced: 10/8/2012 | Value: $45 million
Lead placement agent for Fibrocell Science, Inc. in connection with raising $45 million in a PIPE financing. Strategic Advisor to Fibrocell Science, Inc on its strategic collaboration with Intrexon
Jazz Pharmaceuticals
Announced: 9/6/2012 | Value: $95 Million
Exclusive financial advisor to Jazz Pharmaceuticals on the sale of its Women’s Health Business to Meda AB
Idenix Pharmaceuticals
Announced: 8/2/2012 | Value: $176 million
Financial advisor to Idenix Pharmaceuticals, Inc. on its $176 million follow-on public offering of common stock
BioScrip
Announced: 7/31/2012 | Value: $41 million
Financial advisor to BioScrip Inc. on its acquisition of InfuScience from Cressey & Company
Not Disclosed
Announced: 6/30/2012 | Value: Not Disclosed
Financial advisor to Undisclosed Public Buyer on its acquisition of Healthy Circles
Sun Healthcare
Announced: 6/20/2012 | Value: $275 million
Exclusive financial advisor to Sun Healthcare on its sale to Genesis Healthcare
Lumeris Corporation
Announced: 2/14/2012 | Value: Not Disclosed
Financial advisor to Lumeris Corp. on its acqusition of NaviNet in partnership with Highmark, Horizon Blue Cross Blue Shield of New Jersey and Independence Blue Cross
BioScrip
Announced: 2/2/2012 | Value: $285 million
Financial advisor to BioScrip Inc. on its sale of its community specialty pharmacies and centralized specialty and mail service pharmacy businesses to Walgreens
Idenix Pharmaceuticals
Announced: 11/16/2011 | Value: $61.1 million
Financial advisor to Idenix Pharmaceuticals, Inc. on its $61 million follow-on public offering of common stock
A.P. Pharma
Announced: 6/29/2011 | Value: $24 million
Sole placement agent for AP Pharma in connection with raising $24 million in a PIPE financing
Highmark
Announced: 6/28/2011 | Value: $1.3 billion
Financial advisor to Highmark Inc. in connection with its acquisition of West Penn Allegheny Health System
Trimeris
Announced: 6/13/2011 | Value: $285 million
Exclusive financial advisor to Trimeris Inc. on its reverse merger with Synageva BioPharma Corp
Advanced Vision Research
Announced: 5/3/2011 | Value: $26 million
Exclusive financial advisor to Advanced Vision Research on its sale to Akorn, Inc.
MethylGene
Announced: 3/24/2011 | Value: $35 million
Sole placement agent for MethylGene in connection with raising $35 million in a PIPE financing
Intercell AG
Announced: 2/23/2011 | Value: $45.5 million
Financial advisor to Intercell AG related to the issuance of senior unsecured convertible notes
Sol Amor Hospice
Announced: 1/3/2011 | Value: Not Disclosed
Exclusive financial advisor to Sun Healthcare and its subsidiary SolAmor Hospice on its acquisition of Countryside Hospice
Acadia Pharmaceuticals
Announced: 1/1/2011 | Value: $15 million
Co-placement agent for Acadia Pharmaceuticals Inc. in connection with raising $15 million in a PIPE financing
Aastrom Biosciences
Announced: 12/10/2010 | Value: $22.5 million
Financial advisor to Aastrom Biosciences for its $22.5 million follow-on offering
Neurologix
Announced: 12/6/2010 | Value: $7 million
Lead placement agent for Neurologix, Inc. in connection with raising $7 million in convertible debt
Reata Pharmaceuticals
Announced: 9/23/2010 | Value: $450 million
Strategic advisor to Reata Pharmaceuticals in its landmark ex-US partnership with Abbott Labs
Sun Healthcare
Announced: 8/13/2010 | Value: $238 million
Financial advisor to Sun Healthcare on its equity offering in connection with its restructuring and spinof of its real estate assets
Solstice Neurosciences
Announced: 8/13/2010 | Value: Not Disclosed
Exclusive financial advisor to Solstice Neurosciences, LLC on its sale to US WorldMeds
Trubion Pharmaceuticals
Announced: 8/12/2010 | Value: Up to $140 million
Financial advisor to Trubion Pharmaceuticals on its sale to Emergent Biosolutions
NuPathe
Announced: 8/6/2010 | Value: $50 million
Financial advisor to NuPathe, Inc in connection with its Initial Public Offering
Westcliff Medical Laboratories
Announced: 7/18/2010 | Value: $74 million
Exclusive financial advisor to Westcliff Medical Laboratories on its restructuring and sale to Laboratory Corporation of America
Accolade
Announced: 7/1/2010 | Value: $17 million
Sole placement agent for Accolade LLC on its $17 million Private Placement
Sun Healthcare
Announced: 5/24/2010 | Value: $1.6 billion
Financial advisor to Sun Healthcare on its spin of real estate assets into separately traded Sabra Health Care REIT (SBRA)
Inhibitex
Announced: 10/26/2009 | Value: $23 million
Exclusive placement agent for Inhibitex, Inc. in connection with raising $23 million in a PIPE financing
Threshold Pharmaceuticals
Announced: 10/6/2009 | Value: $35 million
Co-placement agent for Threshold Pharmaceuticals Inc. in connection with raising $35 million in a PIPE financing
Neurogen Corporation
Announced: 8/24/2009 | Value: $11 - 27 million
Exclusive financial advisor to Neurogen Corporation on its Sale to Ligand Pharmaceuticals Incorporated
Reata Pharmaceuticals
Announced: 3/27/2009 | Value: $32 million
Sole placement agent for Reata Pharmaceuticals, Inc on its $32 million Private Placement
Undisclosed Not-for-Profit Managed Care Organization
Announced: 2009 | Value: $37 million
Divestiture of dental insurance business of a not-for-profit insurer
GTC Biotherapeutics
Announced: 11/3/2008 | Value: $15 million
Financial advisor to GTC Biotherapeutics, Inc on its $15 million Convertible Debt financing
Oscient Pharmaceuticals
Announced: 10/21/2008 | Value: $213 million
Dealer manager in connection with debt restructuring and recapitalization
Link Medicine
Announced: 9/30/2008 | Value: $40 million
Sole placement agent for Link Medicine Corporation on its $40 million Private Placement
Threshold Pharmaceuticals
Announced: 7/10/2008 | Value: $18 million
Co-placement agent for Threshold Pharmaceuticals Inc. in connection with raising $18 million in a PIPE financing
My Innerview
Announced: 2008 | Value: Not Disclosed
Exclusive financial advisor in connection with its sale to National Research Corporation (NRCI)
Coram
Announced: 10/12/2007 | Value: $350 million
Exclusive financial advisor in connection with its sale to Apria (AHG)
Universal American (UAM)
Announced: 2007 | Value: $630 million
Financial advisor to priviate equity consortium in connection with its investment to fund the acquisition of MemberHealth
Undisclosed Not-for-Profit Managed Care Organization
Announced: 2007 | Value: $125 million
Acquisition of CompWest
Coram
Announced: 2007 | Value: Not Disclosed
Sale of Canadian infusion portfolio
Sun Healthcare Group
Announced: 12/1/2006 | Value: $19 million
Exclusive financial advisor to Sun Healthcare on its sale of SunPlus Home Health Services to AccentCare Home Health
Sun Healthcare Group
Announced: 10/19/2006 | Value: $625 million
Exclusive financial advisor to Sun Healthcare on its acquisition of Harborside Healthcare
Undisclosed Not-for-Profit Managed Care Organization
Announced: 2006 | Value: $240 million
Acquisition of M-Care
Coram
Announced: 2006 | Value: Not Disclosed
Sale of home infusion portfolio
Pacificare (PHSY)
Announced: 2005 | Value: $9 billion
Sale to UnitedHealthcare (UHG)
Undisclosed Not-for-Profit Managed Care Organization
Announced: 2005 | Value: Not Disclosed
Sale of PPO Business
Sun Healthcare Group
Announced: 5/19/2005 | Value: $246 million
Financial advisor to Sun Healthcare on its acquisition of Peak Medical
Pacificare (PHSY)
Announced: 2005 | Value: Not Disclosed
Acquisition of Pacific Life’s group health insurance business
PresGar Companies
Announced: 2004 | Value: $135 million
Restructuring
PresGar Companies
Announced: 2004 | Value: Not Disclosed
Sale of imaging center portfolio to undislosed buyer
Pacificare (PHSY)
Announced: 2004 | Value: $532 million
Acquisition of American Medical Security Group (AMZ)
Sloans Lake
Announced: 2004 | Value: $45 million
Sale to undiclosed financial buyer
Sun Healthcare Group
Announced: 2/1/2004 | Value: $1.4 billion
Exclusive financial advisor to Sun Healthcare Group on its restructuring
Undisclosed Not-for-Profit Managed Care Organization
Announced: 2004 | Value: $200 million
Structured Financing
Undisclosed Not-for-Profit Managed Care Organization
Announced: 2003 | Value: $150 million
Divestiture
Sun Healthcare Group
Announced: 9/1/2003 | Value: $75 million
Financial advisor to Sun Healthcare on its Senior Debt Financing
Sun Healthcare Group
Announced: 6/17/2003 | Value: $90 million
Exclusive financial advisor to Sun Healthcare on its sale of SunScript Pharmacy Services to Omnicare
Pacificare (PHSY)
Announced: 2002 | Value: $200 million
Advisor to PacifiCare in connection with its High-Yield Financing
The Mentor Network
Announced: 2001 | Value: $126 million
Sale to Madison Dearborn Capital Partners
Magellan Health Services (MGLN)
Announced: 2001 | Value: $250 million
Debt Financing
Schein Pharmaceuticals (SHP)
Announced: 2000 | Value: $1.4 billion
Sale to Watson Pharmaceuticals (WPI)